OpenAlex
PricingAboutJobs
Log inGet started
Work

Luxturna: FDA documents reveal the value of a costly gene therapy

HTML

Year: 2019
Type: article
Source: Drug Discovery Today
DOI: 10.1016/j.drudis.2019.01.019
Author: Jonathan J. Darrow
Institutions: Brigham and Women's Hospital, Harvard University
Language: English

Topic: Retinal Development and Disorders
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Keywords: Luxturna, voretigene neparvovec, gene therapy, drug pricing, inherited retinal degeneration, FDA drug approval, clinical trial endpoints, visual function outcomes, cost-effectiveness, rare disease treatment
SDG: Good health and well-being

Open Access status: closed

Funders: Laura and John Arnold Foundation, Engelberg Foundation, Harvard-MIT Center for Regulatory Science
OpenAlex ID: W2914965689
FWCI: 24.65
Cites: 22
Cited by: 244
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security